In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Evolus (EOLS – Research Report), with a price target of $15.00. The company’s shares closed last Tuesday at $10.80.
According to TipRanks.com, Tsao is a 2-star analyst with an average return of 0.0% and a 37.7% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines.
Currently, the analyst consensus on Evolus is a Strong Buy with an average price target of $15.20, a 20.8% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $18.00 price target.
The company has a one-year high of $14.34 and a one-year low of $5.06. Currently, Evolus has an average volume of 553.9K.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EOLS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.
Read More on EOLS:
- Deutsche Bank’s Analyst Provides Guidance for This Canadian Energy Company
- Blueprint Medicines (BPMC) Gets a Buy Rating from H.C. Wainwright
- H.C. Wainwright Thinks Aptose Biosciences’ Stock is Going to Recover
- Denny’s (DENN) Gets a Hold Rating from Wedbush
- Cirrus Logic (CRUS) Receives a Buy from Needham